Telomir stabilizes Silver(II) in biological form, enabling antimicrobial and wound care applications

Telomir Pharmaceuticals, Inc.

Telomir-1 successfully captured and stabilized both Silver(I) and Silver(II) (Ag²⁺) in a biologically compatible form.
Silver(II) has superior antimicrobial properties but was previously too unstable for medical use.
The breakthrough opens opportunities in advanced wound care, infection-resistant coatings, and antimicrobial treatments.
Company will continue preclinical research and explore regulatory pathways for Silver(II)-complexed Telomir-1.
No financial guidance or revenue impact provided; stage remains preclinical.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.